Back

Kirkland Represents KKR-backed Slayback Pharma in Sale to Azurity Pharmaceuticals

Kirkland & Ellis advised Slayback Pharma LLC on its sale to Azurity Pharmaceuticals Inc, which was announced September 27. The sellers included investment firm KKR and private equity firm Everstone Capital. Slayback is now a wholly-owned subsidiary of privately-held pharmaceutical company Azurity. Slayback focuses on complex generic and specialty pharmaceutical products.

The Kirkland team was led by corporate partners Neil Vohra, Andrew Arons and Jennifer Perkins and associates Lisa Gunter, Sophie Frishberg and Gino Jacobazzi; antitrust & competition partners Rich Cunningham and Samantha Morelli; tax partners Mike Beinus and Vivek Ratnam; debt finance partners Paul Rezvani and associates Ashley Martin and Negin Fatahi; and technology & IP transactions partners Daniel Lewis and Amber Harezlak.

LEGAL DESIRE NEWSLETTER

Where the legal industry reads first.

Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.

No spam. Unsubscribe anytime.

From Legal Desire

Is your firm the one being cited, or the one being skipped?

We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.

Legal Desire Press
https://legaldesire.com/about-us/
Our editorial team that covers judgments, deals, law firm updates, careers and policy across the globe. Coverage is editorially independent; sponsored posts are labeled Partner Content.